Growth Metrics

Evolent Health (EVH) Net Income towards Common Stockholders (2016 - 2026)

Evolent Health has reported Net Income towards Common Stockholders over the past 12 years, most recently at -$429.1 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 1301.7% year-over-year to -$429.1 million; the TTM value through Dec 2025 reached -$579.4 million, down 519.99%, while the annual FY2025 figure was -$579.4 million, 519.99% down from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$429.1 million at Evolent Health, down from -$26.9 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $2.1 million in Q3 2022 and troughed at -$429.1 million in Q4 2025.
  • A 5-year average of -$43.6 million and a median of -$25.7 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: skyrocketed 116.28% in 2022 and later tumbled 1663.64% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at -$5.6 million in 2021, then crashed by 100.97% to -$11.3 million in 2022, then plummeted by 264.75% to -$41.4 million in 2023, then increased by 26.04% to -$30.6 million in 2024, then tumbled by 1301.7% to -$429.1 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for EVH at -$429.1 million in Q4 2025, -$26.9 million in Q3 2025, and -$51.1 million in Q2 2025.